Likewise, the AS01 adjuvant system—comprising MPL, QS-21, and liposomes—has been widely validated in malaria, RSV, and herpes zoster vaccines and is known to promote robust germinal center responses, CD4+ T cell polyfunctionality, and CD8+ T cell cross-presentation [35,36,37,38]. The gene discussed is CD8A; the disease is malaria.